MX2020013894A - Anticuerpos anti-factor xii/xiia y usos de los mismos. - Google Patents
Anticuerpos anti-factor xii/xiia y usos de los mismos.Info
- Publication number
- MX2020013894A MX2020013894A MX2020013894A MX2020013894A MX2020013894A MX 2020013894 A MX2020013894 A MX 2020013894A MX 2020013894 A MX2020013894 A MX 2020013894A MX 2020013894 A MX2020013894 A MX 2020013894A MX 2020013894 A MX2020013894 A MX 2020013894A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- fxii
- factor xii
- xiia
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- H—ELECTRICITY
- H03—ELECTRONIC CIRCUITRY
- H03F—AMPLIFIERS
- H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
- H03F3/45—Differential amplifiers
- H03F3/45071—Differential amplifiers with semiconductor devices only
- H03F3/45076—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier
- H03F3/45475—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier using IC blocks as the active amplifying circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- H—ELECTRICITY
- H03—ELECTRONIC CIRCUITRY
- H03F—AMPLIFIERS
- H03F2203/00—Indexing scheme relating to amplifiers with only discharge tubes or only semiconductor devices as amplifying elements covered by H03F3/00
- H03F2203/45—Indexing scheme relating to differential amplifiers
- H03F2203/45444—Indexing scheme relating to differential amplifiers the CMCL comprising a sample and hold circuit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Power Engineering (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
Abstract
La presente invención proporciona anticuerpos monoclonales que se unen a la proteína del Factor XII (FXII) y métodos de uso de los mismos; en diversas modalidades de la invención, los anticuerpos son anticuerpos completamente humanos que se unen al FXII y a la forma activada del FXII (FXIIa); en algunas modalidades, los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad del FXII, proporcionando así un medio para tratar o prevenir una enfermedad, trastorno o afección asociada con la trombosis en humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687144P | 2018-06-19 | 2018-06-19 | |
PCT/US2019/037865 WO2019246176A1 (en) | 2018-06-19 | 2019-06-19 | Anti-factor xii/xiia antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013894A true MX2020013894A (es) | 2021-05-27 |
Family
ID=67263076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013894A MX2020013894A (es) | 2018-06-19 | 2019-06-19 | Anticuerpos anti-factor xii/xiia y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210203292A1 (es) |
EP (1) | EP3810270A1 (es) |
JP (1) | JP2021527424A (es) |
KR (1) | KR20210022650A (es) |
CN (1) | CN112437682A (es) |
AU (1) | AU2019288299A1 (es) |
CA (1) | CA3104470A1 (es) |
EA (1) | EA202190056A1 (es) |
IL (1) | IL279529A (es) |
MA (1) | MA52966A (es) |
MX (1) | MX2020013894A (es) |
WO (1) | WO2019246176A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230295343A1 (en) * | 2020-06-16 | 2023-09-21 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
EP0534988A1 (en) * | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7378867B1 (en) * | 2002-06-04 | 2008-05-27 | Actel Corporation | Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers |
US6891394B1 (en) * | 2002-06-04 | 2005-05-10 | Actel Corporation | Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US8119137B2 (en) | 2004-12-23 | 2012-02-21 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
PT2374818E (pt) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | Anticorpos com elevada afinidade para o receptor il-6 humano |
US7541838B2 (en) * | 2007-03-27 | 2009-06-02 | Intel Corporation | Transmitter swing control circuit and method |
CN103833855A (zh) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
EP2384766A1 (en) * | 2010-05-03 | 2011-11-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel antibody to a carbonic anhydrase |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
ES2646191T3 (es) | 2011-03-09 | 2017-12-12 | Csl Behring Gmbh | Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales |
LT2734522T (lt) | 2011-07-19 | 2019-02-11 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai |
BR112014001104B1 (pt) * | 2011-07-22 | 2022-12-06 | Csl Behring Gmbh | Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
KR101461652B1 (ko) * | 2011-12-16 | 2014-11-21 | 주식회사 삼양바이오팜 | 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법 |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
TWI613215B (zh) * | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗-大-內皮素-1(big-et-1)抗體及其用途 |
US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
US9260527B2 (en) * | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
KR20150139089A (ko) * | 2014-06-02 | 2015-12-11 | 한국전자통신연구원 | 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로 |
WO2016068803A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
CN111919424A (zh) * | 2018-07-02 | 2020-11-10 | 拉姆伯斯公司 | 利用早期高阶符号检测用于判决反馈均衡的方法和电路 |
-
2019
- 2019-06-19 JP JP2020570743A patent/JP2021527424A/ja active Pending
- 2019-06-19 US US17/253,279 patent/US20210203292A1/en active Pending
- 2019-06-19 EP EP19739793.8A patent/EP3810270A1/en active Pending
- 2019-06-19 EA EA202190056A patent/EA202190056A1/ru unknown
- 2019-06-19 MX MX2020013894A patent/MX2020013894A/es unknown
- 2019-06-19 AU AU2019288299A patent/AU2019288299A1/en active Pending
- 2019-06-19 KR KR1020217001188A patent/KR20210022650A/ko active Search and Examination
- 2019-06-19 MA MA052966A patent/MA52966A/fr unknown
- 2019-06-19 CN CN201980046743.3A patent/CN112437682A/zh active Pending
- 2019-06-19 WO PCT/US2019/037865 patent/WO2019246176A1/en unknown
- 2019-06-19 CA CA3104470A patent/CA3104470A1/en active Pending
-
2020
- 2020-12-17 IL IL279529A patent/IL279529A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210022650A (ko) | 2021-03-03 |
WO2019246176A1 (en) | 2019-12-26 |
IL279529A (en) | 2021-01-31 |
US20210203292A1 (en) | 2021-07-01 |
CN112437682A (zh) | 2021-03-02 |
CA3104470A1 (en) | 2019-12-26 |
JP2021527424A (ja) | 2021-10-14 |
EP3810270A1 (en) | 2021-04-28 |
AU2019288299A1 (en) | 2021-01-14 |
WO2019246176A8 (en) | 2020-10-08 |
MA52966A (fr) | 2021-04-28 |
EA202190056A1 (ru) | 2021-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502560A1 (en) | Anti-c5 antibodies and uses thereof | |
CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
PH12016502064A1 (en) | Human antibodies to middle east respiratory syndrome-coronavirus spike protein | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
PH12019501425A1 (en) | Human antibodies to s. aureus hemolysin a toxin | |
MD3463435T2 (ro) | Anticorpi impotriva alfa sinucleinei și utilizări ale acestora | |
JOP20190292A1 (ar) | استخدام الأجسام المضادة لربط il-1? في علاج السرطان | |
PH12021550255A1 (en) | Anti-npr1 antibodies and uses thereof | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
MX2021001268A (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
PH12018502275A1 (en) | Interferon beta antibodies and uses thereof | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
MX2021004173A (es) | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
MX2020013894A (es) | Anticuerpos anti-factor xii/xiia y usos de los mismos. | |
MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. | |
EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
MX2022003762A (es) | Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma. | |
MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
MX2018004228A (es) | Anticuerpo que se une especificamente a erbb3 y uso de este. |